Suppr超能文献

赛诺菲巴斯德公司在3期试验中展示了其登革热疫苗的疗效。

Sanofi Pasteur shows efficacy of its dengue vaccine in phase 3.

作者信息

Riedmann Eva M

机构信息

Acquisitions Editor; Landes Bioscience; Vienna, Austria.

出版信息

Hum Vaccin Immunother. 2014;10(6):1427. doi: 10.4161/hv.32075.

DOI:10.4161/hv.32075
PMID:25264688
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5396245/
Abstract

Sanofi Pasteur shows efficacy of its dengue vaccine in phase 3 New glioblastoma vaccine: Safe and immunogenic in phase 1 FDA approves sublingual hay fever immunotherapeutic Combining the cancer vaccine DPX-Survivac with immune modulators Two Meningococcal B vaccines receive FDA ‚Breakthrough Therapy’ designation MERS vaccine is technically feasible, but is it commerically feasible? Stemline’s synthetic multi-peptide cancer vaccine enters Phase 2 Evolution of whooping cough bacterium may reduce vaccine effectiveness

摘要

赛诺菲巴斯德公司在3期试验中展示其登革热疫苗的疗效 新型胶质母细胞瘤疫苗：在1期试验中安全且具有免疫原性 美国食品药品监督管理局批准舌下花粉症免疫疗法 将癌症疫苗DPX-Survivac与免疫调节剂相结合 两种B型脑膜炎球菌疫苗获得美国食品药品监督管理局“突破性疗法”认定 中东呼吸综合征疫苗在技术上可行，但在商业上可行吗？ 斯泰姆林公司的合成多肽癌症疫苗进入2期试验 百日咳杆菌的进化可能降低疫苗效力

相似文献

1
Sanofi Pasteur shows efficacy of its dengue vaccine in phase 3.
Hum Vaccin Immunother. 2014;10(6):1427. doi: 10.4161/hv.32075.
2
Sanofi’s successful Phase 3 trials may lead to first-ever dengue vaccine in 2015.
Hum Vaccin Immunother. 2014;10(12):3427. doi: 10.1080/21645515.2014.1003502.
3
From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
Vaccine. 2011 Sep 23;29(42):7229-41. doi: 10.1016/j.vaccine.2011.06.094. Epub 2011 Jul 13.
4
The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries.
PLoS Negl Trop Dis. 2016 Dec 21;10(12):e0005179. doi: 10.1371/journal.pntd.0005179. eCollection 2016 Dec.
5
Dengue vaccine: hypotheses to understand CYD-TDV-induced protection.
Nat Rev Microbiol. 2016 Jan;14(1):45-54. doi: 10.1038/nrmicro.2015.2. Epub 2015 Dec 7.
6
Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward.
Vaccine. 2015 Dec 10;33(50):7100-11. doi: 10.1016/j.vaccine.2015.09.108. Epub 2015 Oct 20.
7
Vaccination Against Dengue: Challenges and Current Developments.
Annu Rev Med. 2016;67:387-404. doi: 10.1146/annurev-med-091014-090848. Epub 2015 Oct 23.
8
Preparing for dengue vaccine introduction: recommendations from the 1st dengue v2V International Meeting.
PLoS Negl Trop Dis. 2013 Sep 26;7(9):e2261. doi: 10.1371/journal.pntd.0002261. eCollection 2013.
9
Challenges in the interpretation of dengue vaccine trial results.
PLoS Negl Trop Dis. 2013 Aug 29;7(8):e2126. doi: 10.1371/journal.pntd.0002126. eCollection 2013.
10
Development of Sanofi Pasteur tetravalent dengue vaccine.
Rev Inst Med Trop Sao Paulo. 2012 Oct;54 Suppl 18:S15-7. doi: 10.1590/s0036-46652012000700007.

引用本文的文献

1
Pediatric infectious diseases: getting research evidence into practice and generation of new evidence.
Front Pediatr. 2014 Dec 8;2:138. doi: 10.3389/fped.2014.00138. eCollection 2014.

本文引用的文献

1
Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice.
Vaccine. 2014 May 30;32(26):3169-3174. doi: 10.1016/j.vaccine.2014.04.016. Epub 2014 Apr 13.
2
Rapid increase in pertactin-deficient Bordetella pertussis isolates, Australia.
Emerg Infect Dis. 2014 Apr;20(4):626-33. doi: 10.3201/eid2004.131478.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验